| 引用本文: | | 冯素娟,耿 丹,沈 燕,张 毅*.[cn_title][J].[journal_cn_name],2023,[volume]([issue]):1396-1399.[点击复制] |
| | FENG Sujuan,GENG Dan,SHEN Yan,ZHANG Yi*.[en_title][J].[journal_en_name],2023,[volume]([issue]):1396-1399.[点击复制] |
|
| 摘要: |
| 目的：了解某三级医院血液透析产ESBLs大肠埃希菌株感染现况，分析血液透析患者因院内产ESBLs大肠埃希菌株感染造成的经济损失。方法：前瞻性研究分析2021年2月~2022年4月在该院行维持性血液透析患者150名的资料，进行尿液细菌培养，将产ESBLs大肠埃希菌株感染患者作为病例组1，普通大肠埃希菌株感染（除外产ESBLs大肠埃希菌株感染）作为病例组2，无尿路感染患者作为病例组3。比较病例组1、2、3组感染相关因素和经济成本。结果：大肠埃希菌感染26例，其中产ESBLs大肠埃希菌株感染12例。血液透析患者医院患者床位费、诊疗费、检查费、治疗费、化验费、护理费、药物费和其他费用病例组1>病例组2>病例组3；其中药物费的差值最大。结论：血液透析患者院内感染产ESBLs大肠埃希菌株会导致患者直接经济损失增加，医院应重点加强院内感染的防控、规范抗生素的使用。 |
| 关键词: 血液透析 尿路感染 超广谱β-内酰胺酶 经济损失 |
| DOI： |
|
| 基金项目:江苏省医院协会医院管理创新专项研究课题（JSYGY-3-2021-PJ68）；南通市卫生健康委员会科研课题（MB2021026；MB2021013）；江苏省中医药科技发展计划项目（MS2021060）；南通大学临床基础研究专项一般项目（2022JY003；2022HY003）；南通市科技计划项目（MS12021041） |
|
| Infection of ESBLs-producing Escherichia Coli Strains in Hemodialysis Patients in a Grade A Tertiary Hospital Assessment of Direct Economic Loss△ |
| FENG Sujuan,GENG Dan,SHEN Yan,ZHANG Yi* |
| (Hemodialysis Center;Neurosurgery Department，Nantong，The Second Affiliated Hospital of Nantong University) |
| Abstract: |
| Objective：To understand the current situation of ESBLs-producing Escherichia coli infection during hemodialysis in a certaintertiary hospital，and to analyze the economic losses caused by ESBLs-producing escherichia coli infection in hemodialysis patients. Methods：A prospective study analyzed the data of 150 patients who underwent maintenance hemodialysis in our hospital from February 2021 to April 2022. Urine bacterial culture was carried out. Using a case-control research method，ESBLs-producing Escherichia coli strains were tested. Infected patients were regarded as case group 1，common Escherichia coli infection（excluding ESBLs-producing Escherichia coli infection）was regarded as case group 2，and patients without urinary tract infection were regarded as group3. The infection-related factors and economic costs were compared between case groups 1 and 2 and group3. Results：26 cases were infected by Escherichia coli，among which 12 cases were infected by ESBLs-producing Escherichia coli. Hemodialysis patients’ hospital bed fee，diagnosis and treatment fee，examination fee，treatment fee，laboratory fee，nursing fee，drug fee and other expenses in case group 1>case group 2>group3. The largestdifference isdrug fee. Conclusion：Nosocomial infection of ESBLs-producing Escherichia coli strains in hemodialysis patients will lead to increased direct economic losses. Hospitals should focus on strengthening the prevention and control of nosocomial infection and standardize the use of antibiotics. |
| Key words: Hemodialysis Urinary Tract Infection Extendedspectrum β-lactamase EconomicLoss |
